Mycophenolate mofetil and myasthenia gravis

Lupus

Volumn 14, Issue SUPPL. 1, 2005, Pages

  Ciafaloni, Emma ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Immunosuppression; Myasthenia gravis; Mycophenolate mofetil; Mycophenolic acid; Treatment

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EDROPHONIUM; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE;

ABDOMINAL CRAMP; ALOPECIA; ANOREXIA; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; BLOOD TOXICITY; BONE MARROW TOXICITY; BRADYCARDIA; BRAIN INFARCTION; CANCER; CATARACT; CHILL; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FASCICULATION; FEVER; FRACTURE; HEADACHE; HEMORRHAGIC CYSTITIS; HEPATITIS C; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; MOOD DISORDER; MUSCLE CRAMP; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NEPHROTOXICITY; NEUROMUSCULAR TRANSMISSION; PANCREATITIS; PRIORITY JOURNAL; SALIVATION DISORDER; SKIN DISEASE; TREMOR; VASOMOTOR DISORDER; VOMITING;

EID: 16244406556     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2118oa     Document Type: Article

References (17)

1. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-368.
2. Jaretzki A, Barohn RJ, Ernstoff RM et al. Myasthenia gravis. Recommendations for clinical research standards. Neurology 2000; 55: 16-23.
3. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7-15.
4. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high dose iv. Immunoglobulin in myasthenia gravis. Annals of Neurology 1997; 41: 789-796.
5. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Annals of Neurology 1984; 15: 291-298.
6. Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurology 1988; 235: 449-453.
7. Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Annals of Neurology 1984; 15: 602-605.
8. Palace J, Newsom-Davis J, Lecky B, and the Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998; 50: 1778-1783.
9. Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology 1986; 36: 35-39.
10. Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988; 38: 258-261.
11. Tyndall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporin in myasthenia gravis. N Eng J Med 1987; 316: 719-724.
12. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000; 55: 448-450.
13. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998; 51: 912-913.
14. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001; 56: 97-99.
15. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis:a double-blind, placebo-controlled pilot study. Annals of the New York Academy of Science 2003; 998: 494-499.
16. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001; 56: 94-96.
17. Meriggioli M, Ciafaloni E, Al-Hayk KA. et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003; 61: 1438-1440.